Metamizol Tarbis (Metamizole Magnesium)

Metamizole inhibits cyclooxygenase enzymes, which reduces the production of prostaglandins that mediate pain and fever. In addition, it influences central pain pathways in the spinal cord, providing a combined peripheral and central analgesic effect that also lowers body temperature.

The specific dose of Metamizol Tarbis is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual health factors. Healthcare professionals follow local prescribing guidelines and adjust the regimen as needed for safety and efficacy.

Safety data for metamizole in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. Therefore, it should only be used when the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.

To request Metamizol Tarbis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metamizole offers rapid analgesic and antipyretic effects similar to non‑steroidal anti‑inflammatory drugs (NSAIDs) but with a different chemical class. Unlike opioids, it does not act on opioid receptors, reducing the risk of dependence, but it carries a rare risk of severe blood disorders that are not typical of standard NSAIDs.

Metamizol Tarbis should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Metamizol Tarbis is administered orally. The tablets or oral formulation should be swallowed whole with a full glass of water. It can be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any accompanying fluids.

The most serious adverse reactions include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic responses such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be advised to seek immediate medical attention if they develop signs of infection, rash, or breathing difficulties.

Metamizol Tarbis should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, those with a history of severe blood dyscrasias, and patients with significant renal or hepatic impairment unless closely monitored. Pregnant or breastfeeding women should only use it when clearly indicated by a healthcare professional.